Shkreli Fallout Continues: PhRMA Seems To Soften Stance On REMS Legislation
This article was originally published in The Pink Sheet Daily
Executive Summary
Brand drug representative tells Senate subcommittee there are problems with bill that would make it easier for generics to obtain samples, but did not appear interested in scrapping it.
You may also be interested in...
REMS Could Block ANDAs With 'Legitimate Business Justification' In Senate Bill
Sen. Leahy's reintroduced CREATES Act allows generic sponsors to sue innovators who fail to provide sufficient quantities of REMS covered products, but seems to give wide latitude to courts; bill reflects Congress' broader focus on generic drugs to address drug pricing issue.
REMS Could Block ANDAs With 'Legitimate Business Justification' In Senate Bill
Sen. Leahy's reintroduced CREATES Act allows generic sponsors to sue innovators who fail to provide sufficient quantities of REMS covered products, but seems to give wide latitude to courts; bill reflects Congress' broader focus on generic drugs to address drug pricing issue.
REMS Reform Seems Distant Goal For Generics After Limited Support At US House Hearing
Although panelists expressed concerns about REMS misuse as barrier to competition, Republicans did not appear interested in the topic.